Review Article: GLP-1 Receptor Agonists @NEJMgroup
Review Article: GLP-1 Receptor Agonists @NEJMgroup
Uploaded April 2026 | Updated September 2026, 1 week ago
GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal.

Read the Review Article “GLP-1 Receptor Agonists” at NEJM.org.

#endocrinology #nejm
Review Article: GLP-1 Receptor AgonistsNEJM Interview: Raja-Elie Abdulnour on the need for clinicians and AI systems to refrain from exp...Clinical Decisions: Fast Track in Internal Medicine ResidencyClement Lee, M.D., Playing Doctordle — August 19, 2026When No Ones WatchingNEJM Interview: Jerry Avorn on the role of litigation in addressing product-related damage to hea...Endovascular Treatment of Medium-Vessel-Occlusion Strokes (ORIENTAL-MeVO)Clinical Practice: Otitis Media in Young ChildrenMeet the EquationDr. Glaucomflecken Explains: Tecovirimat for the Treatment of Mpox (STOMP/A5418)Dr. Glaucomflecken Explains: Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (KEYNOTE-905)OpenAI’s Karan Singal on HealthBench and the Future of Medical AI
NEJM Group |

Review Article: GLP-1 Receptor Agonists

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER